Neurolief Grows Leadership with Dr. Owen Muir's Appointment
Neurolief, a prominent player in brain stimulation aimed at addressing mental health and neurological challenges, has officially appointed Dr. Owen Muir as its fractional Chief Medical Officer (CMO). His extensive background in psychiatry and familiarity with medical devices regulated by the FDA will be crucial as the company advances its mission of providing effective brain stimulation therapies for individuals dealing with major depressive disorders.
Dr. Muir’s Expertise and Background
Dr. Muir holds dual board certifications in child and general psychiatry, showcasing his skill in handling complex mood disorders. He currently serves as a Clinical Assistant Professor of Medicine at a renowned institution's psychiatry and behavioral sciences department. Furthermore, Dr. Muir co-founded Fermata, which prioritizes neuromodulation in medical practices. His active participation in the integration of cutting-edge technologies within clinical environments positions him at the forefront of improving mental health care outcomes.
Strategic Vision for Neurolief
Expressing enthusiasm about Dr. Muir's appointment, Scott Drees, CEO of Neurolief, remarked, "We are thrilled to have Dr. Muir join our leadership team. His profound knowledge of brain stimulation therapies and commitment to enhancing mental health care aligns seamlessly with our vision. We trust that his guidance will be instrumental in the successful launch of Proliv™Rx, our innovative solution for countless patients seeking relief from traditional treatments that fall short.”
Preparation for the Launch of Proliv™Rx
Dr. Muir's role becomes vital as Neurolief is gearing up to introduce its newest offering—Proliv™Rx, specifically designed for Treatment-Resistant Depression (TRD). This therapy, granted FDA Breakthrough Designation, is the first of its kind that offers a home-based brain stimulation solution, having shown clinical efficacy in trials for patients who have not responded to standard therapeutic approaches. This marks a pivotal leap forward in the mental health sphere.
Commitment to Patient Care
In Dr. Muir's own words, "As a physician committed to supporting individuals battling depression, I have always aspired to make effective and accessible treatment options available to those who struggle with the inadequacies of traditional antidepressants. Being part of Neurolief's team as CMO allows me the privilege to contribute to making Proliv™Rx available to those suffering from treatment-resistant depression. I am excited about the potential of this breakthrough technology to provide relief to millions still in search of hope.”
Revolutionizing Depression Treatment
Proliv™Rx heralds a significant advancement in non-invasive brain neuromodulation, allowing for treatment within clinical environments or the patient's own home. By employing three adaptive output channels, Proliv™Rx provides targeted electrical stimulation to critical neural pathways that influence mood regulation.
Enhanced Patient Interaction
In addition to its sophisticated brain stimulation capabilities, Proliv™Rx features an interactive mobile application and a cloud-based data tracking system. This cohesive setup enables healthcare providers to remotely monitor patient progress, facilitating data-driven analyses to customize treatment plans. Such innovations ultimately contribute to improved patient outcomes.
About Neurolief
Neurolief is an innovative neuromodulation company committed to advancing treatments for mental health and neurological disorders. The firm pioneered a novel, non-invasive multi-channel brain stimulation technology designed to engage multiple neural pathways concurrently, which modulates the brain regions responsible for mood and pain management. Currently, Neurolief's Relivion™MG therapy is approved in various global markets, including the US, Europe, and Japan, for migraine treatment.
Frequently Asked Questions
What is Neurolief's mission?
Neurolief aims to develop safe and effective brain stimulation therapies for mental health and neurological disorders.
Who is Dr. Owen Muir?
Dr. Owen Muir is a dual board-certified psychiatrist with significant experience in brain stimulation therapies and is now Neurolief's fractional Chief Medical Officer.
What is Proliv™Rx?
Proliv™Rx is Neurolief's innovative therapy designed for Treatment-Resistant Depression, which offers at-home brain stimulation solutions.
How does Proliv™Rx work?
Proliv™Rx utilizes targeted electrical stimulation to key neural pathways, helping to regulate mood and improve overall mental health.
What sets Neurolief apart?
Neurolief's technology is unique as it targets multiple neural pathways simultaneously, enhancing the effectiveness of treatment for patients.
